The Event
On 17 October 2026, the Food Safety and Standards Authority of India (FSSAI) issued show-cause notices to two of India's largest consumer goods companies. The allegations are serious, but they are not final findings. Both companies have been asked to explain their positions within a stipulated period, and unsatisfactory responses could lead to further action under food safety laws.
The timing is notable. FSSAI announced the notices on social media, alongside enforcement actions against smaller players. This public posture suggests the regulator is moving from behind-the-scenes corrections to more visible enforcement. For investors and consumers, the key question is what this means for the companies involved and the broader nutrition sector.
The notice to Hindustan Unilever concerns its Horlicks Mother's Plus Kesar 400 g product. FSSAI examined a complaint, the product label, advertisements and an e-commerce listing. It found two claims "potentially misleading" and in contravention of the Food Safety and Standards (Advertising and Claims) Regulations, 2018.
The first claim is "Healthy Birth Weight" on the label. The second is "For baby's healthy birth weight" in advertisements. FSSAI's objection is straightforward: the wording implies that consuming the product itself would confer health benefits relating to a baby's birth weight, which the regulator says is inconsistent with applicable rules.
The e-commerce listing compounded the issue. The product name included "For Pregnancy and Lactation with Protein for Birth Weight and DHA for Brain Development - No Added Sugar" as part of the title. FSSAI cited non-compliance with prescribed requirements for such claims.
A second notice covers Horlicks Women's Plus Chocolate Nutrition Drink. FSSAI flagged claims including "Nutrition for Strong Bones," "Clinically Proven to Help Improve Bone Strength in 6 Months," and "Improves Bone Health" as misleading or non-compliant. It also questioned the use of "Healthy Muscles," saying it violated provisions governing the use of the word "healthy" in food claims. The "No Added Sugar" claim was considered potentially misleading because the product contains maltodextrin.
The notice to Nestlé India concerns Resource Renal vanilla-flavoured powder, intended for the dietary management of people with conservatively treated chronic kidney disease. This is a different category of problem.
FSSAI's notice states that Nestlé India had not obtained this mandatory clearance, rendering the product non-compliant.
Additionally, the product label did not display the prescribed vegetarian or non-vegetarian symbol, which FSSAI says violates the Food Safety and Standards (Labelling and Display) Regulations, 2020.
Nestlé India's filings contain no disclosure of Resource Renal or any food for special medical purpose approval. The company's medical nutrition business is described as a joint venture with Dr. Reddy's, with brands such as Peptamen and Celevida. How Resource Renal fits into this structure is not publicly disclosed. Investor Presentation +1
Neither company discloses revenue for the specific products named in the notices. Any rupee estimate of the impact would therefore be speculation. What can be sized is the broader exposure.
For HUL, Horlicks sits inside the Foods segment, which reported revenue of ₹14,061 crore in FY26, representing 22% of consolidated revenue with a 20% segment margin. In Q1 FY27, Foods revenue reached ₹3,480 crore with 7% underlying sales growth. Management has said Horlicks and Boost both grew at double digits, marking the fifth consecutive quarter of positive volume growth for the category. Investor Presentation +2
For Nestlé India, total revenue from operations was ₹23,155 crore in FY26. Q1 FY27 revenue grew 25.4% year-on-year, the fastest quarterly rate in the recent series. Medical nutrition is largely outside the core reporting, sitting in a joint venture structure. Annual Report +2
The share prices reflect recent market pressure but not yet the FSSAI notices, which were announced on a Saturday. HUL's last close was ₹1,893.80, down 3.48% over one month. Nestlé India's last close was ₹1,265.50, down 8.60% over one month.
No source quantifies the remediation costs. The channels are clear: label and pack changes, e-commerce listing corrections, legal and regulatory responses, and possibly reformulation or re-approval.
The scenarios differ by company. For HUL, the issue is primarily communication. Remediation is largely within the company's control: revised labels, ad copy and marketplace listings. Reformulation is unlikely unless a claim is tied to the formulation. The "No Added Sugar" claim on Horlicks Women's Plus, disputed because of maltodextrin, may require repositioning or ingredient changes.
Fixing it requires a regulatory approval process, which depends on the regulator's timeline. Sales may be affected in the interim. The missing symbol fix is simple, but the approval gap is not.
Past penalties provide context. Nestlé's disclosed penalties for misbranding or substandard products ranged from ₹10,000 to ₹2,00,000 per order, all under appeal. These amounts are immaterial against the company's revenue. The larger risks are commercial: stop-sale, reputational damage and management time. Annual Report +1
The notices reveal different risk profiles. Nestlé India's exposure is to market-entry and licensing controls. This is its third recent FSSAI matter, after a June 2026 Maggi notice and a September 2026 infant-formula action. The company states that 100% of its marketing communications comply with ASCI and FSSAI regulations. Repeated notices could erode confidence in that statement. Other +2
HUL's exposure is to claims substantiation and channel control. Its annual report already lists labelling inaccuracies as an operational risk, with potential consequences for regulatory compliance. The notices test how well those controls work in practice. Annual Report +1
Both companies face a common challenge: FSSAI is now examining product names and e-commerce listings, not just labels. Companies selling health-positioned products online will need ongoing monitoring of listings, claims approval workflows and regulatory-affairs capacity. This adds recurring costs, though the filings give no quantification.
The immediate focus is on the company responses. Neither has disclosed the notices yet, and markets have not had a chance to react. The next trading day is Monday, 19 October.
The medium-term focus is on enforcement. FSSAI has asked licensing authorities and e-commerce platforms to take action. Whether this leads to stop-sale, delisting or licence action will determine the commercial impact.
The longer-term focus is on compliance governance. Expect tighter regulatory sign-off on product launches, claims and listings. Regulatory affairs should have a veto point before products hit the market. For investors, the key takeaway is that the nutrition sector is entering a period of stricter oversight. Companies that treat compliance as a cost center rather than a strategic capability may find themselves on the wrong side of the next notice.
